摘要
Abstract
Objective To investigate the effect and immune function changes of using mycobacterium F ..U.36 in treating patients with pulmonary tuberculosis .Methods From May 2013 to July 2014 , 86 cases of tuberculosis patients were enrolled, the patients were divided according to the order of admission into observation group (43 cases) and control group (43 cases).All patients were treated with rifampin(0.45 g), isoniazid(0.3 g), and amine butanol(0.75 g),once a day, observation group patients also received mycobacterium F .U.36(1.72 μg/ml).After treatment’s clinical efficacy, including symptoms , improvement of lung CT and recurrence were observed in all patients , changes in immune function in two groups of patients before treatment and after 18 weeks of treatment were observed .Results The total symptom improvement rate of the observation group (97.67%) was significantly higher than control group (83.72%), the difference were statistically signifi-cant (χ2 =11.900, P <0.01); after treatment, observation group’s CT lung lesions overall improvement rate (97.68%) was significantly higher than control group (81.39%), the difference was statistically significant (χ2 =11.179, P <0.05);after treatment, observation group’s IgG (8.63 ±3.76) g /L, IgM (1.13 ±0.53) g /L, CD4+(32.10 ±13.20)%, CD8+(32.30 ±8.20)%was significantly better than the control group ’s (6.64 ±3.25) g /L, (0.91 ±0.47)) g /L, (38.60 ±7.60)%, (27.70 ±5.60)%, the difference was statistically significant ( t =2.626, t =2.0375, t =2.798, t =3.038, P <0.05); no recurrence were found in the observation group , and control group had a recurrence of 8 cases (18.6%), the difference was statistically significant (χ2 =8.821, P <0.05).Conclusion For the initial treatment of tu-berculosis patients , mycobacteriumphlei F .U.36 can significantly improve symptoms , lesions and immune function , it is worth widely used.关键词
肺结核/草分枝杆菌F.U.36/临床效果/免疫功能Key words
Tuberculosis/Mycobacteriumphlei F .U.36/Clinical effect/Immune function
